Rituximab in combination with chemotherapy for the treatment of chronic lymphocytic leukaemia in clinical practice
ConclusionChemoimmunotherapy with rituximab is feasible and safe in a wide variety of clinical settings in CLL, including the treatment of older patients with comorbidities (ClinicalTrials. gov NCT01178086).This article is protected by copyright. All rights reserved.
Source: European Journal of Haematology - Category: Hematology Authors: Marcel Reiser, Steffen D örfel, Manfred Hensel, Mark Hoesl, Wolf‐Oliver Jordan, Michael Koenigsmann, Dirk Meyer, Dietmar Reichert, Andreas Schwarzer, Moritz Marquardt, Kerstin Kellershohn, Kathleen Jentsch‐Ullrich Tags: Original Article Source Type: research
More News: Chemotherapy | Chronic Leukemia | Chronic Lymphocytic Leukemia | Clinical Trials | Hematology | Jordan Health | Leukemia | Middle East Health | Nutrition | Rituxan | Study | Treanda